- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02593058
Positive Emotions Program for Schizophrenia (PEPS) (PEPS-RCT)
Positive Emotions Program for Schizophrenia (PEPS): A Randomized Controlled Study on Improving Pleasure and Motivation in Schizophrenia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Recent literature has distinguished the negative symptoms associated with a diminished capacity to experience (apathy, anhedonia) from those which are associated with a limited capacity for expression (emotional blunting, alogia). The apathy-anhedonia syndrome tends to be associated with a poorer prognosis than the symptoms related to diminished expression, suggesting that it is the more severe facet of the psychopathology. However the efficacy of drug-based treatments and psychological interventions on primary negative symptoms remains limited. There is a clear clinical need for developing treatments for negative symptoms.
The Positive Emotions Programs for Schizophrenia (PEPS) teaches skills to help overcome defeatist thinking and to increase the anticipation and maintenance of positive emotions. PEPS involves eight one-hour group sessions, administered using visual and audio materials as part of a PowerPoint presentation of slides projected onto a screen.
The goal of the study is to establish if PEPS is clinically effective by using a randomized, controlled and assessor-blind trial. A combination of PEPS plus treatment as usual will be compared to treatment as usual alone. Participants diagnosed with a schizophrenia spectrum disorder will undergo either intervention for eight weeks. Testing will evaluate individuals' current psychopathology and ability to savor pleasure and will be performed at the time of inclusion, at the end of the eight-week intervention and at six month follow-up.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Vaud
-
Lausanne, Vaud, Switzerland, 1004
- Institut et Haute Ecole de la Santé la Source & Service de psychiatrie communautaire du Département de psychiatrie du Centre Hospitalier Universitaire Vaudois
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- a psychotic disorder according to ICD 10 (F20 or F25), diagnoses having been established by experienced clinicians;
- presenting a score of at least 2 on the overall SANS anhedonia scale;
- French-speaking;
- Ability to consent measured with the San Diego Brief Assessment of Capacity to Consent (UBACC)-a decisional capacity instrument.
Exclusion Criteria:
- evidence of organic brain disease, clinically significant concurrent medical ill/ness, or learning disability;
- no understanding of the study protocol as assessed with the San Diego Brief Assessment of Capacity to Consent (UBACC)-a decisional capacity instrument
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: PEPS+TAU
Eight one-hour weekly sessions of Positive Emotions Program for Schizophrenia (PEPS) + Treatment as Usual (TAU)
|
Each session of PEPS includes relaxation-meditation exercise, review of homework task given during the previous session, exercises to challenge defeatist beliefs.
According to the session's theme, participants learn skills to improve their anticipation or maintenance of pleasure such as savoring a pleasant experience, expressing emotions by increasing behavioral expression, capitalizing on positive moments, and anticipating pleasant moments.
A simple homework task is assigned to be done between each session.
The pedagogical concept underpinning the program was built according to Kolb and Kolb's model of experiential learning.
The program uses a collaborative, egalitarian approach.
Other Names:
TAU consists of psychiatric management by a clinical team composed of at least one psychiatrist and a social worker and/or a psychiatric nurse with additional access to community treatment or hospital admission.
Treatment involves antipsychotic medication, regular office-based or community contact with the clinical team for treatment monitoring, and socialization groups, therapy, and psychoeducational groups.
No attempts have been made to standardize this treatment as TAU is tailored to the patient's specific needs.
Other Names:
|
|
Active Comparator: Treatment As Usual (TAU)
Treatment as usual - with no attempts to standardize this treatment as TAU is tailored to the patient's specific needs
|
TAU consists of psychiatric management by a clinical team composed of at least one psychiatrist and a social worker and/or a psychiatric nurse with additional access to community treatment or hospital admission.
Treatment involves antipsychotic medication, regular office-based or community contact with the clinical team for treatment monitoring, and socialization groups, therapy, and psychoeducational groups.
No attempts have been made to standardize this treatment as TAU is tailored to the patient's specific needs.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change on the composite score of apathy/avolition and anhedonia/asociality ot the Scale for the Assessment of Negative Symptoms (SANS).
Time Frame: Change from Baseline composite score at 2 months
|
The Scale for the Assessment of Negative Symptoms (SANS) measures schizophrenia's deficit symptoms within the framework of schizophrenic disorders.
It comprises 25 items, scored from 0 to 5. A definition of each item, including examples, facilitates a better understanding of the scale's content.
The rating system is ordinal, from 0 (absent) to 5 (severe).
The twenty-five items are grouped into five components: 1) withdrawal or emotional poverty; 2) alogia (lack of speech); 3) avolition and apathy (lack of energy, lack of initiative); 4) anhedonia and social withdrawal (loss of interests); 5) attention.
The scale was translated into French with acceptable validity.
The composite score for the avolition-apathy and anhedonia-social withdrawal scale will be used as the main outcome variable.
|
Change from Baseline composite score at 2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change on the Calgary Depression Scale for Schizophrenia (CDSS)
Time Frame: Change from Baseline CDSS score at 2 months
|
The Calgary Depression Scale for Schizophrenia (CDSS) includes nine items: depression, hopelessness, self-depreciation, guilty ideas of reference, pathological guilt, morning depression, early wakening, suicide, and observed depression.
This scale has been validated in French.
|
Change from Baseline CDSS score at 2 months
|
|
Change on the Savoring Belief Inventory (SBI)
Time Frame: Change from Baseline SBI total score at 2 months
|
The Savoring Belief Inventory (SBI) is a self-reported scale for measuring beliefs about one's capacity for savoring things.
The scale has twenty four items, including a positive scale (twelve items) and a negative scale (twelve items).
The scale has good validity and a high test-re-test reliability.
It measures a person's thinking regarding his/her capacity to savor positive experiences, in terms of past experiences, current experiences, and future anticipation.
The total SBI score will be used as a secondary outcome variable.
|
Change from Baseline SBI total score at 2 months
|
|
Change on the Temporal Experience of Pleasure Scale (TEPS)
Time Frame: Change from Baseline TEPS scales at 2 months
|
The Temporal Experience of Pleasure Scale (TEPS) is a self-reported scale and contains eighteen items included in two sub-scales: anticipatory pleasure (ten items) and consummatory pleasure (eight items).
Items targeting anticipatory pleasure reflect the pleasure felt when anticipating a positive or pleasant stimulus.
Items measuring consummatory pleasure refer to the direct pleasure experienced upon exposure to a stimulus.
Items can be general or specific.
The response to items falls on a six-point Likert scale from 1 (very false for me) to 6 (very true for me).
This scale has been validated in French.
|
Change from Baseline TEPS scales at 2 months
|
|
Change on the Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS)
Time Frame: Change from Baseline ACIPS scales at 2 months
|
The Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS) is designed to assess one's ability to experience pleasure in the interpersonal domain.
It is a seventeen-item self-reported measure that consists of seven anticipatory and ten consummatory items.
The ACIPS is scored on a six-point Likert scale, ranging from 1 (very false for me) to 6 (very true for me).
The format is therefore quite similar to that of TEPS.
The difference between the two scales lies mainly in terms of the items' content.
|
Change from Baseline ACIPS scales at 2 months
|
|
Change on the Social Functioning Scale (SFS)
Time Frame: Change from Baseline SFS at 8 months
|
The Social Functioning Scale (SFS) is constructed to assess those areas of functioning that are crucial to the community maintenance of individuals with schizophrenia.
This is a reliable, valid, sensitive instrument and responsive to change.
This last scale will be completed by the case-manager of the participant.
|
Change from Baseline SFS at 8 months
|
|
Change on the Calgary Depression Scale for Schizophrenia (CDSS)
Time Frame: Change from Baseline CDSS score at 8 months
|
The Calgary Depression Scale for Schizophrenia (CDSS) includes nine items: depression, hopelessness, self-depreciation, guilty ideas of reference, pathological guilt, morning depression, early wakening, suicide, and observed depression.
This scale has been validated in French.
|
Change from Baseline CDSS score at 8 months
|
|
Change on the composite score of apathy/avolition and anhedonia/asociality ot the Scale for the Assessment of Negative Symptoms (SANS)
Time Frame: Change from Baseline composite score at 8 months
|
The Scale for the Assessment of Negative Symptoms (SANS) measures schizophrenia's deficit symptoms within the framework of schizophrenic disorders.
It comprises 25 items, scored from 0 to 5. A definition of each item, including examples, facilitates a better understanding of the scale's content.
The rating system is ordinal, from 0 (absent) to 5 (severe).
The twenty-five items are grouped into five components: 1) withdrawal or emotional poverty; 2) alogia (lack of speech); 3) avolition and apathy (lack of energy, lack of initiative); 4) anhedonia and social withdrawal (loss of interests); 5) attention.
The scale was translated into French with acceptable validity.
The composite score for the avolition-apathy and anhedonia-social withdrawal scale will be used as the main outcome variables.
|
Change from Baseline composite score at 8 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jérôme Favrod, Institut et Haute Ecole de la Santé la Source & Service de psychiatrie communautaire du Département de psychiatrie du Centre Hospitalier Universitaire Vaudois
Publications and helpful links
General Publications
- Favrod J, Nguyen A, Fankhauser C, Ismailaj A, Hasler JD, Ringuet A, Rexhaj S, Bonsack C. Positive Emotions Program for Schizophrenia (PEPS): a pilot intervention to reduce anhedonia and apathy. BMC Psychiatry. 2015 Sep 29;15:231. doi: 10.1186/s12888-015-0610-y.
- Favrod J, Giuliani F, Ernst F, Bonsack C. Anticipatory pleasure skills training: a new intervention to reduce anhedonia in schizophrenia. Perspect Psychiatr Care. 2010 Jul;46(3):171-81. doi: 10.1111/j.1744-6163.2010.00255.x.
- Golay P, Thonon B, Nguyen A, Fankhauser C, Favrod J. Confirmatory Factor Analysis of the French Version of the Savoring Beliefs Inventory. Front Psychol. 2018 Feb 19;9:181. doi: 10.3389/fpsyg.2018.00181. eCollection 2018.
- Chaix J, Golay P, Fankhauser C, Nguyen A, Gooding DC, Favrod J. Confirmatory Factor Analysis of the French Version of the Anticipatory and Consummatory Interpersonal Pleasure Scale. Front Psychol. 2017 Jul 28;8:1296. doi: 10.3389/fpsyg.2017.01296. eCollection 2017.
- Nguyen A, Frobert L, McCluskey I, Golay P, Bonsack C, Favrod J. Development of the Positive Emotions Program for Schizophrenia: An Intervention to Improve Pleasure and Motivation in Schizophrenia. Front Psychiatry. 2016 Feb 17;7:13. doi: 10.3389/fpsyt.2016.00013. eCollection 2016.
- Favrod J, Nguyen A, Chaix J, Pellet J, Frobert L, Fankhauser C, Ismailaj A, Brana A, Tamic G, Suter C, Rexhaj S, Golay P, Bonsack C. Improving Pleasure and Motivation in Schizophrenia: A Randomized Controlled Clinical Trial. Psychother Psychosom. 2019;88(2):84-95. doi: 10.1159/000496479. Epub 2019 Feb 18.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 105319_163355 / 1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Fundació Institut de Recerca de l'Hospital de la...Recruiting
-
First Affiliated Hospital of Fujian Medical UniversityNot yet recruiting
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Newron Pharmaceuticals SPARecruitingTreatment-resistant SchizophreniaUnited States
-
Bradley LegaRecruiting
-
Central Institute of Mental Health, MannheimRecruitingSchizophrenia | Treatment Resistant SchizophreniaGermany
-
All India Institute of Medical Sciences, BhubaneswarCompletedTreatment Resistant SchizophreniaIndia
-
Elazığ Mental Health and Diseases HospitalCompleted
-
Dr. Lutfi Kirdar Kartal Training and Research HospitalCompletedSchizophrenia DisorderTurkey (Türkiye)
Clinical Trials on Positive Emotions Program for Schizophrenia
-
Vanderbilt UniversityNationwide Children's HospitalCompleted
-
Human Development Research Foundation, PakistanUniversity of Liverpool; Institute of Psychiatry, WHO Collaborating Center...CompletedDepression | Anxiety | Psychological Distress | Emotional ProblemPakistan
-
Northwestern UniversityBraveNetCompletedMusculoskeletal Pain | Chronic PainUnited States
-
Yale UniversityNational Center for Advancing Translational Sciences (NCATS); Academic Pediatric...CompletedSocial Emotional WellnessUnited States
-
Vanderbilt UniversityAmerican Psychological FoundationCompletedBehavioral Symptoms | Depressive Disorder | Depression | Mood Disorders | Anhedonia | Stress | Mental Disorder | Mood DisturbanceUnited States
-
Butler HospitalAmerican Foundation for Suicide PreventionCompletedSchizophrenia | SuicideUnited States
-
US Department of Veterans AffairsCompletedSchizophrenia | Schizophrenic DisorderUnited States
-
Centre hospitalier de Ville-Evrard, FranceRecruitingSchizophrenic DisordersFrance
-
The University of Hong KongNot yet recruitingDepressive Symptoms | BPSD | Expressed Emotion